The encyclopedia · Strategy & Leadership · Strategic decision · 2003–2024
Kaya Skin Clinic was Marico's ambitious bet — a decade of losses and a 75% stock collapse
Harsh Mariwala's premium skincare chain lost ₹116 crore in FY23, debt hit ₹142 crore, and the stock lost three-quarters of its value since listing.
Kaya Limited · 2023-03
What happened
Kaya was founded in 2003 by Harsh Mariwala, the billionaire chairman of Marico (owner of brands like Parachute coconut oil and Saffola). The idea was to build a premium, clinic-based skincare business in India — a market that had no organized chain of dermatology-led skin clinics. At its peak, Kaya operated 94 clinics across 27 Indian cities and 23 clinics in the Middle East, staffed by over 100 dermatologists.
Marico demerged Kaya into a separate listed entity in 2013, and the company listed on the NSE and BSE in August 2015. The demerger was meant to let Kaya grow independently, but it also ended the financial shelter of Marico's FMCG profits. From listing onward, Kaya posted a net loss in every financial year except one. Revenue, which had reached ₹382 crore in FY16, fell to ₹377 crore by FY23, while the net loss ballooned from ₹27 crore to ₹116 crore over the same period. Debt rose from ₹30 crore to ₹142 crore.
The business model had structural problems. The 'cure' model — treating specific skin conditions — had high acquisition costs and low repeat rates because cured patients did not return. A shift to 'cure and care' alienated the dermatologists who had been the core of the service. Competition from over 200 boutique clinics in major cities eroded pricing power. And rapid expansion had stretched management: Mariwala admitted in 2017 that the company had 'leadership and executive issues.' By 2023 the stock was trading at ₹361, down 49% over five years and over 75% since listing.
Why it happened
- The clinic model was capital-intensive and required expensive dermatologists at every location, making it difficult to achieve the unit economics of a product business.
- A strategy pivot from 'cure' to 'cure and care' confused the brand's positioning and alienated the dermatologists who drove referrals.
- Rapid expansion into 27 cities stretched management and operational capabilities, leading to inconsistent service quality across clinics.
- The demerger from Marico removed the financial cushion of FMCG profits, leaving Kaya to fund its losses and expansion with debt that reached ₹142 crore.
- Competition from over 200 independent clinics and specialists in major cities meant Kaya could not command the pricing premium needed to cover its cost structure.
The lesson
Expensive specialists at every location make a service business hard to scale. When the parent's profits are gone, the unit economics have to work — or debt compounds faster than clinics can open.
Aftermath
Kaya continued operating its clinics in India and the Middle East, but the mounting losses and debt left it with few options. The company attempted a post-COVID refurbishment and expansion into Tier 2 and 3 cities, but the financial trajectory showed no sign of reversal. By 2023 the stock had lost three-quarters of its listing price, and the accumulated losses had consumed most of the equity raised since the demerger.
Sources
- Outlook Business — Why Harsh Mariwala Has Failed To Find Cure For His Lacklustre Kaya Clinic (2023)
- Wikipedia — Kaya Limited
spotted an error? The club wants to know.
More like this
Veeko International went from HK$2.23B revenue and 222 stores to HK$421M and 89
Porcelain, Singapore's premium spa brand, entered provisional liquidation after 17 years
Skincity shut down after 14 years — the owner stopped investing after the Kicks merger
Somewhere, someone solved the problem this company failed at. 2nd Opinion →
Comments · 0
Sign in to join the comments.